Viewpoint: A shot in the arm for generics producers
Domino inksThere is nowhere to hide from the Falsified Medicines Directive. It impacts generics producers in the same way as any other drug manufacturer or re-packager selling into Europe. With just under 48 months to go before the deadline, which is likely to be mid-2018, the clock is ticking for all producers to get their house in order.
The subject was hot on the agenda at the European Generics Association (EGA) meeting in Madrid earlier this month. As generics manufacturers often supply products with much lower margins than patented drug producers, their budgets are restricted when it comes to new investment – which is why many of them have been holding out until the last minute to find the ‘best-fit’ solution for their businesses.
Related Posts
Spain claims Gibraltar derives £150m from tobacco smuggling
Nearly a third of Gibraltar's income is derived from tobacco smuggling, according...
International – Only a quarter of brand owners participate in anti-counterfeiting coalitions, survey reveals
Data shared at last week’s Intellectual Property Owners Association (IPO) annual...
CARDINAL COMPONENTS, INC., and INFRATRAC are entering into an exclusive partnership to introduce an anti-counterfeit chemical fingerprint, LUTRACORE
Worried about counterfeiters? Cardinal Components, Inc., and its exclusive...
House chief rejects boycott of China products
House Speaker Feliciano “Sonny” R. Belmonte Jr. yesterday rejected calls to...